Results 261 to 270 of about 22,249,811 (294)

PD-1: CD28 chimeric receptors enhance phenotypic and functional features of T cell subsets. [PDF]

Res Pharm Sci
Feghhi-Najafabadi S, Riazi-Rad F, Shokrgozar MA, Abdoli S, Taheri FH, Arashkia A, Sharifzadeh Z.   +6 more
europepmc   +1 more source

Targeting PD-1⁺ T cells with chimeric antigen receptors to reduce the HIV reservoir. [PDF]

Sci Adv
Ermellino L, Banga R, Georgakis S, Kadzioch NP, Procopio F, Alcaraz-Serna A, Alfageme-Abello O, Porret R, Cecchin R, Orfanakis M, Schelling R, Brenna C, Can DC, Foglierini M, Chén OY, Perez L, Fenwick C, Perreau M, Petrovas C, Speck RF, Pantaleo G, Muller YD.   +21 more
europepmc   +1 more source

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events. [PDF]

Curr Oncol
Burghaus-Zhang J, Schulz C, Ramelyte E, Mangana J, Özistanbullu D, Kleemann J, Enk A, Hassel JC.   +7 more
europepmc   +1 more source

Discovery of d‑Miniprotein Inhibitors of PD-1/PD-L1 Interaction via Mirror-Image Phage Display against Synthetic d‑PD‑1. [PDF]

JACS Au
Zhou H, Wu H, Zhong Z, Blasco P, Zeng J, Wang J, Liu H, Li X.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PD-1 and Autoimmunity

Critical Reviews™ in Immunology, 2011
An initiating T cell response requires both costimulatory signaling and T cell receptor/MHC binding. The immune system balances positive and negative costimulatory signal pathways to activate and deactivate T cells. This review focuses primarily on PD-1 and its ligands, which form a crucial inhibitory costimulatory pathway for maintaining peripheral ...
Shimpei, Kasagi, Seiji, Kawano, Shunichi, Kumagai   +2 more
openaire   +2 more sources

PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

Blood, 2008
AbstractProgrammed death-1 (PD-1)–PD-1 ligand (PD-L) signaling system is involved in the functional impairment of T cells such as in chronic viral infection or tumor immune evasion. We examined PD-L expression in lymphoid cell lines and found that they were up-regulated on Hodgkin lymphoma (HL) and several T-cell lymphomas but not on B-cell lymphomas ...
Ryo, Yamamoto, Momoko, Nishikori, Toshio, Kitawaki, Tomomi, Sakai, Masakatsu, Hishizawa, Masaharu, Tashima, Tadakazu, Kondo, Katsuyuki, Ohmori, Masayuki, Kurata, Takamasa, Hayashi, Takashi, Uchiyama   +10 more
openaire   +2 more sources

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Preparative Biochemistry & Biotechnology, 2019
Targeting the interaction interface is an effective strategy to obtain programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-L1) nanobody blockers. To validate this strategy, the interaction interface between PD-1 and the PD-L1 extracellular domain were analyzed using Cn3D 4.1. The peptide PD-1125-136 located at the interface of PD-1 was selected as the
Biyan, Wen, Lin, Zhao, Yuchu, Wang, Chuangnan, Qiu, Zhimin, Xu, Kunling, Huang, He, Zhu, Zemin, Li, Huangjin, Li   +8 more
openaire   +2 more sources